References

  • Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935-944.
  • Butzner M, Riello RJ III, Sarocco P, Desai NR. Adverse drug effects across patients with heart failure: a systematic review. Am J Manag Care. 2022;28(3):e113-e120.
  • Chang PP, Chambless LE, Shahar E, et al. Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the atherosclerosis risk in communities study). Am J Cardiol. 2014;113(3):504-510.
  • de Almeida FA, Al MJ, Koymans R, et al. Impact of hospitalisation on health-related quality of life in patients with chronic heart failure. Health Qual Life Outcomes. 2020;18(262):1-10.
  • Dunbar SB, Tan X, Lautsch D, et al. Patient-centered outcomes in HFrEF following a worsening heart failure event: a survey analysis. J Card Fail. 2021;27(8):877-887.
  • Fiuzat M, Hamo CE, Butler J, et al. Optimal background pharmacological therapy for heart failure patients in clinical trials. JACC. 2022;79(5):504-510.
  • Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol. 2007;50(8):768-777. 
  • Fry M, McLachlan S, Purdy S, et al. The implications of living with heart failure; the impact on everyday life, family support, co-morbidities and access to healthcare: a secondary qualitative analysis. BMC Family Practice. 2016;17(139):1-8.
  • Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):11G-17G.
  • Greene SJ, Felker GM, Butler J. Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. Eur J Heart Fail. 2019;21(1):121-124.
  • Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30-38.
  • He H, Baka T, Balschi J, et al. Novel small-molecule troponin activator increases cardiac contractile function without negative impact on energetics. Circ: Heart Failure. 2022; 15(3):e009195.
  • Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421.
  • Huusko J, Tuominen S, Studer R, et al. Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure. ESC Heart Failure. 2020;7:2406–2417.
  • Ito S, Pislaru C, Miranda WR, et al. Left ventricular contractility and wall stress in patients with aortic stenosis with preserved or reduced ejection fraction. JACC Cardiovasc Imaging. 2020;13(2):357-369.
  • Khan MS, Tahhan AS, Vaduganathan M, et al. Trends in prevalence of comorbidities in heart failure clinical trials. Eur J Heart Fail. 2020;22(6):1032-1042.
  • Malik A, Gill GS, Lodhi, FK, et al. Prior heart failure hospitalization and outcomes in patients with heart failure with preserved and reduced ejection fraction. Am J Med. 2020;133(1):84-94.
  • Mallick A, Gandhi PU, Gaggin HK, Ibrahim N, Januzzi JL. The importance of worsening heart failure in ambulatory patients: definition, characteristics, and effects of amino-terminal pro-B-type natriuretic peptide guided therapy. J Am Coll Cardiol. 2016;4(9):749-755.
  • Mann DL, Chakinala M. Heart failure and cor pulmonale. In: Longo DL et al, eds. Harrison’s Principles of Internal Medicine. 18th ed. McGraw‑Hill; 2012:1901‑1915.
  • Okuhara Y, Asakura M, Orihara Y, et al. Reduction in left ventricular ejection fraction is associated with subsequent cardiac events in outpatients with chronic heart failure. Sci Rep. 2019;9(1):17271.
  • Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J, Malik FI, Houdusse A. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun. 2017;8:190.
  • Psotka MA, Gottlieb SS, Francis GS, et al. Cardiac calcitropes, myotropes, and mitotropes. J Am Coll Cardiol. 2019;73(18):2345‑2353.
  • Rethy L, McCabe M, Pool LR, et al. Contemporary rates of hospitalization for heart failure in young and middle-aged adults in a diverse US state. Cir Cardiovasc Qual Outcomes. 2020;13(11):e007014.
  • Rørth R, Jhund PS, Yilmaz MB, et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circ Heart Fail. 2020;13(2):e006541.
  • Saczynski JS, Go AS, Magid DJ, et al. Patterns of comorbidity in older adults with heart failure: the Cardiovascular Research Network PRESERVE study. J Am Geriatr Soc. 2013;61(1):26-33.
  • Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260-266.
  • Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112(24):3738-3744.
  • Spudich JA. Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J. 2014;106:1236-1249.
  • Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circ. 2022;145:e153–e639.
  • Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020;13(11):e006977.
  • Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014–2020). PharmacoEconomics. 2020;38(11):1219-1236.
  • Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev. 2021;26(6):1359-1370.